GlassScriptPhysician profile
Thu Minh Vu
NPI 1427681741
$2,925.61
in general payments reported to CMS, 2019-2025
15 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $100 · 2024: $1,223 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $734.20 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Phathom Pharmaceuticals, INC. | $457.09 | 2024 | Voquezna |
| Redhill Biopharma INC. | $279.08 | 2024-2025 | Talicia |
| Amgen INC. | $261.04 | 2025 | Evenity, Repatha |
| Lilly USA, LLC | $169.49 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $166.95 | 2024-2025 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $150.00 | 2025 | |
| Aimmune Therapeutics, INC. | $147.78 | 2025 | Zenpep |
| Abiomed | $137.41 | 2025 | |
| Genzyme Corporation | $125.67 | 2025 | |
| Gilead Sciences, INC. | $120.25 | 2025 | Vemlidy |
| Biogen, INC. | $100.00 | 2023 | Tysabri |
| Exact Sciences Corporation | $39.27 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $22.33 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.05 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thu Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.